1. Home
  2. CTW vs IMUX Comparison

CTW vs IMUX Comparison

Compare CTW & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTW Cayman Class A Ordinary Shares

CTW

CTW Cayman Class A Ordinary Shares

HOLD

Current Price

$1.75

Market Cap

171.0M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.40

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
IMUX
Founded
2013
2016
Country
Japan
United States
Employees
N/A
66
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.0M
155.8M
IPO Year
2025
2013

Fundamental Metrics

Financial Performance
Metric
CTW
IMUX
Price
$1.75
$7.40
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $43.09
AVG Volume (30 Days)
13.8K
★ 382.7K
Earning Date
10-15-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.00
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.41
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.51
52 Week High
$3.14
$17.43

Technical Indicators

Market Signals
Indicator
CTW
IMUX
Relative Strength Index (RSI) 37.28 36.21
Support Level $1.19 $6.35
Resistance Level $1.88 $8.60
Average True Range (ATR) 0.32 0.65
MACD -0.02 0.19
Stochastic Oscillator 5.48 46.67

Price Performance

Historical Comparison
CTW
IMUX

About CTW CTW Cayman Class A Ordinary Shares

CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: